HONG KONG – Looking to solidify its pipeline and extend patent protection for some of its top selling oncology products, Takeda Pharmaceutical Co. has launched a series of late-stage trials, including a Phase III clinical trial in Asia for its oral proteasome inhibitor MLN9708 (ixazomib citrate). Much of the work will be done in China.